ZUG, Switzerland and BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRSP), a biopharmaceutical company focused on ...

CRISPR Therapeutics AG (NASDAQ:CRSP) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates ...

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) on November 5 and set a ...

Robert W. Baird analyst Jack Allen has maintained their neutral stance on CRSP stock, giving a Hold rating yesterday. Jack Allen has given his ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has been given an average recommendation of “Hold” by the nineteen brokerages that are covering the company, Marketbeat Ratings reports. Two ...

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (NASDAQ:CRSP) on Thursday, setting a price target of $166, which is ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San ...